Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to redu… Read more
Oragenics Inc - Asset Resilience Ratio
Oragenics Inc (OGEN) has an Asset Resilience Ratio of 0.15% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2022)
This chart shows how Oragenics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Oragenics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $17.94K | 0.15% |
| Total Liquid Assets | $17.94K | 0.15% |
Asset Resilience Insights
- Limited Liquidity: Oragenics Inc maintains only 0.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Oragenics Inc Industry Peers by Asset Resilience Ratio
Compare Oragenics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF |
Biotechnology | 25.67% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Exicure Inc
NASDAQ:XCUR |
Biotechnology | 0.00% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Oragenics Inc (2009–2022)
The table below shows the annual Asset Resilience Ratio data for Oragenics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.12% | $17.94K | $14.76 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $7.21 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $4.31 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $5.78 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $11.13 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $16.83 Million | -- |
| 2012-12-31 | 0.59% | $62.00K | $10.49 Million | -20.33pp |
| 2011-12-31 | 20.92% | $265.00K | $1.27 Million | -6.64pp |
| 2010-12-31 | 27.55% | $476.00K | $1.73 Million | -48.94pp |
| 2009-12-31 | 76.49% | $2.45 Million | $3.20 Million | -- |